Cargando…

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome

CONTEXT: Polycystic ovary syndrome (PCOS), a highly prevalent endocrine disorder characterized by hyperandrogenism, is the leading cause of anovulatory infertility. OBJECTIVE: This proof-of-concept study evaluated clinical efficacy and safety of the neurokinin 3 (NK3) receptor antagonist fezolinetan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fraser, Graeme L, Obermayer-Pietsch, Barbara, Laven, Joop, Griesinger, Georg, Pintiaux, Axelle, Timmerman, Dirk, Fauser, Bart C J M, Lademacher, Christopher, Combalbert, Jean, Hoveyda, Hamid R, Ramael, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Online Only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372662/ https://www.ncbi.nlm.nih.gov/pubmed/34000049 http://dx.doi.org/10.1210/clinem/dgab320

Ejemplares similares

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
por: Santoro, Nanette, et al.
Publicado: (2020)

OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
por: Fraser, Graeme, et al.
Publicado: (2019)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
por: Fraser, Graeme L., et al.
Publicado: (2020)

Comparison of 3 Different AMH Assays With AMH Levels and Follicle Count in Women With Polycystic Ovary Syndrome
por: Moolhuijsen, Loes M E, et al.
Publicado: (2022)

Characteristics of polycystic ovary syndrome throughout life
por: Louwers, Yvonne V., et al.
Publicado: (2020)

Follicle Stimulating Hormone Receptor (FSHR) Polymorphisms and Polycystic Ovary Syndrome (PCOS)
por: Laven, Joop S. E.
Publicado: (2019)

Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)
por: Hoveyda, Hamid R., et al.
Publicado: (2015)

Translation of the Modified Polycystic Ovary Syndrome Questionnaire (mPCOSQ) and the Polycystic Ovary Syndrome Quality of Life Tool (PCOSQOL) in Dutch and Flemish Women with PCOS
por: Jiskoot, Geranne, et al.
Publicado: (2023)

Change in Androgenic Status and Cardiometabolic Profile of Middle-Aged Women with Polycystic Ovary Syndrome
por: van der Ham, Kim, et al.
Publicado: (2023)

Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome
por: Skorupskaite, Karolina, et al.
Publicado: (2020)

Evidence From Men for Ovary-independent Effects of Genetic Risk Factors for Polycystic Ovary Syndrome
por: Zhu, Jia, et al.
Publicado: (2021)

Bone morphogenetic proteins and the polycystic ovary syndrome
por: van Houten, E Leonie AF, et al.
Publicado: (2013)

The cardiovascular risk profile of middle‐aged women with polycystic ovary syndrome
por: Meun, Cindy, et al.
Publicado: (2019)

Targeting Elevated GnRH Pulsatility to Treat Polycystic Ovary Syndrome
por: Abbara, Ali, et al.
Publicado: (2021)

Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome
por: Hu, Lili, et al.
Publicado: (2022)

Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women
por: Pawsey, Steve, et al.
Publicado: (2021)

Lifestyle treatment in women with polycystic ovary syndrome: predictors of weight loss and dropout
por: Jiskoot, Geranne, et al.
Publicado: (2022)

Probiotic vs. placebo and metformin: probiotic dietary intervention in polycystic ovary syndrome – A randomized controlled trial
por: Borzan, Valentin, et al.
Publicado: (2023)

Hyperandrogenemia in Polycystic Ovary Syndrome: Exploration of the Role of Free Testosterone and Androstenedione in Metabolic Phenotype
por: Lerchbaum, Elisabeth, et al.
Publicado: (2014)

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists
por: Cena, Hellas, et al.
Publicado: (2020)

Sexual Function in Women With Polycystic Ovary Syndrome: Design of an Observational Prospective Multicenter Case Control Study
por: Pastoor, Hester, et al.
Publicado: (2020)

Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study
por: Berni, Thomas R, et al.
Publicado: (2021)

Intrafollicular Concentrations of the Oocyte-secreted Factors GDF9 and BMP15 Vary Inversely in Polycystic Ovaries
por: Kristensen, Stine Gry, et al.
Publicado: (2022)

Are Dieting and Dietary Inadequacy a Second Hit in the Association with Polycystic Ovary Syndrome Severity?
por: Huijgen, Nicole A., et al.
Publicado: (2015)

Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome(†)(‡)
por: Teede, Helena J, et al.
Publicado: (2018)

Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome
por: Teede, Helena J., et al.
Publicado: (2018)

Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome
por: Teede, Helena J., et al.
Publicado: (2018)

Polycystic Ovary Syndrome: A Brain Disorder Characterized by Eating Problems Originating during Puberty and Adolescence
por: Steegers-Theunissen, Régine P. M., et al.
Publicado: (2020)

Changes in eating behavior through lifestyle treatment in women with polycystic ovary syndrome (PCOS): a randomized controlled trial
por: Jiskoot, Geranne, et al.
Publicado: (2022)

Impact of Short-Term Isoflavone Intervention in Polycystic Ovary Syndrome (PCOS) Patients on Microbiota Composition and Metagenomics
por: Haudum, Christoph, et al.
Publicado: (2020)

Erratum. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome
por: Teede, Helena J, et al.
Publicado: (2019)

Vitamin D Concentrations at Term Do Not Differ in Newborns and Their Mothers with and without Polycystic Ovary Syndrome
por: Kollmann, Martina, et al.
Publicado: (2021)

Response to Letter to the Editor From Jialal: “Higher Incidence of Metabolic Syndrome in Black Women With Polycystic Ovary Disease: A Longitudinal Study”
por: Lee, Iris, et al.
Publicado: (2022)

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial
por: Neal-Perry, Genevieve, et al.
Publicado: (2023)

“Veozah (Fezolinetant): A Promising Non‐Hormonal Treatment for Vasomotor Symptoms in Menopause”
por: Shaukat, Ayesha, et al.
Publicado: (2023)

Androgen and Anti-Mullerian Hormone Concentrations at Term in Newborns and Their Mothers with and without Polycystic Ovary Syndrome
por: Kollmann, Martina, et al.
Publicado: (2019)

The Genetics of Polycystic Ovary Syndrome: An Overview of Candidate Gene Systematic Reviews and Genome-Wide Association Studies
por: Hiam, Danielle, et al.
Publicado: (2019)

The Salivary Microbiome in Polycystic Ovary Syndrome (PCOS) and Its Association with Disease-Related Parameters: A Pilot Study
por: Lindheim, Lisa, et al.
Publicado: (2016)

The role of B cells in immune cell activation in polycystic ovary syndrome
por: Ascani, Angelo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fv70obm8prhq3p6hodq66gp474